Momenta Pharmaceuticals Inc (MNTA): John E Bishop , Senior VP, Pharmaceutical Scie of Momenta Pharmaceuticals Inc sold 2,843 shares on Apr 19, 2016. The Insider selling transaction was reported by the company on Apr 19, 2016 to the Securities and Exchange Commission. The shares were sold at $9.57 per share for a total value of $27,207.51 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Feb 24, 2016, John E Bishop (Senior VP, Pharmaceutical Scie) sold 329 shares at $9.73 per share price.On Feb 24, 2016, Craig A Wheeler (President) sold 1,688 shares at $9.95 per share price.Also, On Feb 24, 2016, Richard P Shea (SVP, CFO) sold 227 shares at $9.65 per share price.On Feb 24, 2016, James M. Roach (Senior VP, Development and Chi) sold 250 shares at $9.65 per share price.
Momenta Pharmaceuticals: On Monday, Apr 18, 2016 heightened volatility was witnessed in Momenta Pharmaceuticals which led to swings in the share price. The shares opened for trading at $9.55 and hit $9.74 on the upside , eventually ending the session at $9.69, with a gain of 1.25% or 0.12 points. The heightened volatility saw the trading volume jump to 3,41,671 shares. The 52-week high of the share price is $25.56 and the company has a market cap of $670 M . The 52-week low of the share price is at $7.86.
Currently the company Insiders own 7.6% of Momenta Pharmaceuticals shares according to the proxy statements.In the past twelve weeks, the net percent change held by company insiders has changed by -2.32%.Institutional Investors own 85.66% of Momenta Pharmaceuticals shares.During last six month period, the net percent change held by insiders has seen a change of 8.22%.
Momenta Pharmaceuticals Inc. (Momenta) is a biotechnology company focused on developing generic versions of drugs biosimilars and therapeutics for oncology and autoimmune disease. The Company has three product areas: Complex Generics Biosimilars and Novel Therapeutics. The Companys product a generic version of Lovenox (enoxaparin sodium injection) was approved by the United States Food and Drug Administration. The Company is developing Complex Generics such as Enoxaparin Sodium Injection and M356. The Company is developing Bosimilars including M923 and M834. The Company is developing Novel Therapeutics including Necuparanib. The Company is developing M356 as a generic version of Copaxone. The Company is developing M923 a biosimilar of HUMIRA. The Company is developing M834 as a biosimilar of ORENCIA.